[1] |
Okegawa T, Pong RC, Li Y, et al. The role of cell adhesion molecule in cancer progression and its application in cancer therapy[J]. Acta biochim Pol, 2004, 51(2): 445-457.
|
[2] |
Skubitz KM, Skubitz AP. Two new synthetic peptides from the N-domain of CEACAM1(CD66a) stimulate neutrophil adhesion to endothelial cells[J]. Biopolymers, 2011, 96(1): 25-31.
|
[3] |
Obrink B. On the role of CEACAM1 in cancer[J]. Lung cancer, 2008, 60(3): 309-312.
|
[4] |
Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity[J]. Nat Rev Immunol, 2006, 6(6): 433-446.
|
[5] |
Bamberger AM, Briese J, Götze J, et al. Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells[J]. Carcinogenesis, 2006, 27(3): 483-490.
|
[6] |
Lucka L, Fernando M, Grunow D, et al. Identification of Lewis x structures of the cell adhesion molecule CEACAM1 from human granulocytes[J]. Glycobiology, 2005, 15(1): 87-100.
|
[7] |
Tsukada M, Wakai T, Matsuda Y, et al. Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression predicts metachronous pulmonary metastasis and poor survival in patients with hepatoblastoma[J]. J Pediatr Surgery, 2009, 44(8): 1522-1528.
|
[8] |
Busch C, Hanssen TA, Wagener C, et al. Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition[J]. Hum Pathol, 2002, 33(3): 290-298.
|
[9] |
Wang JL, Sun SZ, Qu X, et al. Clinicopathological significance of CEACAM1 gene expression in breast cancer[J]. Chin J Physiol, 2011, 54(5): 332-338.
|
[10] |
Arabzadeh A, Chan C, Nouvion AL, et al. Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer[J]. Oncogene, 2013, 32(7): 849-860.
|
[11] |
Tilki D, Singer BB, Shariat SF, et al. CEACAM1: a novel urinary marker for bladder cancer detection[J]. Eur Urol, 2010, 57(4): 648-654.
|
[12] |
Ebrahimnejad A, Streichert T, Nollau P, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells[J]. Am J Pathol, 2004, 165(5): 1781-1787.
|
[13] |
Sivan S, Suzan F, Rona O, et al. Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients[J]. Clin Dev Immunol, 2012, 2012: 290536.
|
[14] |
Serra S, Asa SL, Bamberger AM, et al. CEACAM1 expression in pancreatic endocrine tumors[J]. Appl immunohistochem Mol Morphol, 2009, 17(4): 286-293.
|
[15] |
李文,张鹏,许刚柱,等. siRNA下调CEACAM1基因表达对人胶质瘤SHG44细胞增殖和凋亡的影响[J].山西医科大学学报, 2014, 45(11): 1018-1022.
|
[16] |
Duxbury MS. CEACAM1 cytoplastic expression is closely related to tumor angiogenesis and poorer relapse-free survival after curative resection of hepatocellular carcinoma[J]. World J Surg, 2011, 35(10): 2266-2267.
|
[17] |
Kiriyama S, Yokoyama S, Ueno M, et al. CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, 21(Suppl 4): S505-514.
|
[18] |
Zhou CJ, Liu B, Zhu KX, et al. The different expression of carcinoembryonic antigen-related cell adhesion molecule1(CEACAM1) and possible roles in gastric carcinomas[J]. Pathol Res Pract, 2009, 205(7): 483-489.
|
[19] |
Liu JN, Shang Guan YM, Qi YZ, et al. The evaluation of SOX9 expression and its relationship with carcinoembryonic antigen-related cell adhesion molecule 1 in gastric neoplastic and nonneoplastic lesions[J]. An Diagn Pathol, 2012, 16(4): 235-244.
|
[20] |
Ergün S, Kilik N, Ziegeler G, et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor[J]. Mol Cell, 2000, 5(2): 311–320.
|
[21] |
Horst AK, Ito WD, Dabelstein J, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo[J]. J Clin Invest, 2006, 116(6): 1596-1605.
|
[22] |
Nouvion AL, Oubaha M, Leblanc S, et al. CEACAM1: a key regulator of vascular permeability[J]. J Cell Sci, 2010, 123(Pt 24): 4221-4230.
|
[23] |
Gerstel D, Wegwitz F, Jannasch K, et al. CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation[J]. Oncogene, 2011, 30(41): 4275-4288.
|
[24] |
Horst AK, Bickert T, Brewig N, et al. CEACAM1+ myeloid cells control angiogenesis in inflammation[J]. Blood, 2009, 113(26): 6726-6736.
|
[25] |
Lu R, Kujawski M, Pan H, et al. Tumor Angiogenesis Mediated by Myeloid Cells Is Negatively Regulated by CEACAM1[J]. Cancer Res, 2012, 72(9): 2239-2250.
|
[26] |
Samineni S, Zhang Z, Shively JE. Carcinoembryonic antigen-related cell adhesion molecule1 negatively regulates granulocyte colony-stimulating factor production by breast tumor-associated macrophages that mediate tumor angiogenesis[J]. Int J Cancer, 2013, 133(2): 394-407.
|
[27] |
Arabzadeh A, Chan C, Nouvion AL, et al. Host-related carcinoembryonic antigen cell adhesion molecule1 promotes metastasis of colorectal cancer[J]. Oncogene, 2013, 32(7): 849-860.
|
[28] |
Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer[J]. Cancer Res, 2004, 64(24): 8932-8938.
|
[29] |
Tilki D, Irmak S, Oliveira-Ferrer L, et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer[J]. Oncogene, 2006, 25(36): 4965-4974.
|
[30] |
Kirshner J, Hardy J, Wilczynski S, et al. Cell-Cell Adhesion Molecule CEACAM1 is Expressed in Normal Breast and Milk and Associates with β1 Integrin in a 3D Model of Morphogenesis[J]. J Mol Histol, 2004, 35(3): 287-299.
|
[31] |
Markel G, Achdout H, Katz G, et al. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients[J]. Eur J Immunol, 2004, 34(8): 2138-2148.
|
[32] |
Zhang H1, Eisenried A, Zimmermann W, et al. Role of CEACAM1 and CEACAM20 in an In Vitro Model of Prostate Morphogenesis[J]. Plos One, 2013, 8(1): e53359.
|
[33] |
Huang J, Hardy JD, Sun Y, et al. Essential role of biliary glycoprotein (CD66a) in morphogenesis of the human mammary epithelial cell line MCF10F[J]. J Cell Sci, 1999, 112(pt23): 4193-4205.
|
[34] |
Markel G, Ortenberg R, Seidman R, et al. Systemic dysregulation of CEACAM1 in melanoma patients[J]. Cancer Immunol Immunothe, 2010, 59(2): 215-230.
|
[35] |
Simeone DM1, Ji B, Banerjee M, et al. CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer[J]. Pancreas, 2007, 34(4): 436-443.
|
[36] |
Motz GT, Coukos G. Deciphering and reversing tumor immune suppression[J]. Immunity, 2013, 39(1): 61-73.
|
[37] |
Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic[J]. Front Oncol, 2015, 4(1):385.
|
[38] |
Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion[J]. Nature, 2015, 517(7534): 386-390.
|